MedPath

Evaluation of Salivary Adseverin, 1-Alpha Defensin and sRANKL Levels of Individuals With Different Periodontal Diseases

Not Applicable
Recruiting
Conditions
Periodontal Diseases
Interventions
Diagnostic Test: Saliva obtaining
Registration Number
NCT06402877
Lead Sponsor
Izmir Katip Celebi University
Brief Summary

: The aim of this study is; detection of Adseverin,1-alpha Defensin,sRANKL(soluble RANKL) levels in saliva samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine Adseverin,1-alpha Defensin,sRANKL(soluble RANKL) levels in the biological samples.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria

Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.) At least twenty permanent teeth in the mouth Non-smoker No medication for continuous use Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.

Not in pregnancy or lactation period. For the periodontitis group that has not received periodontal treatment in the last 6 months For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.

Exclusion Criteria

Any oral or systemic disease Regularly using a systemic medication During pregnancy or lactation Received periodontal treatment within the last 6 months. Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months Smokers are not included in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PeriodontitisSaliva obtainingFull-mouth clinical periodontal measurements recorded and saliva obtained.
Healthy PeriodontiumSaliva obtainingFull-mouth clinical periodontal measurements recorded and saliva obtain
GingivitisSaliva obtainingFull-mouth clinical periodontal measurements recorded and saliva obtained.
Primary Outcome Measures
NameTimeMethod
The total amount of 1-Alpha Defensin in saliva24 hours after taking the clinical measurements at the first visit

The total amount of 1-Alpha Defensin in saliva

The total amount of Adseverin in saliva24 hours after taking the clinical measurements at the first visit]

The total amount of Adseverin in saliva

The total amount of sRANKL in saliva24 hours after taking the clinical measurements at the first visit

The total amount of soluble RANKL in saliva

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Izmir Katip Çelebi University Department of Periodontology

🇹🇷

İzmir, Çiğli, Turkey

© Copyright 2025. All Rights Reserved by MedPath